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  Diabetic polyneuropathy is one of the complications of 
chronic diabetes related to long-standing hyperglycemia and is 
a common cause of morbidity in diabetic patients. Diabetic 
polyneuropathy develops under the conditions of chronic hy-
perglycemia, associated with metabolic derangements and 
cardiovascular risk factors [1]. Recently, the close relationships 
between diabetic polyneuropathy and micro- or macroangi-
opathy have been reported [2-4]. Results from a population-
based study of type 2 diabetic patients in Sweden showed that 
peripheral sensory neuropathy, assessed by 10 g monofilament 
and vibration perception threshold was associated with reti-
nopathy and overt nephropathy [2]. In the EURODIAB Pro-
spective Complications Study, the risk factors for cardiovascu-
lar disease including hypertension, total cholesterol, smoking, 
and previous cardiovascular disease increased the incidence of 
abnormal vibration perception threshold in type 1 diabetes 
mellitus [5]. Several studies have reported associations between 
diabetic polyneuropathy and cardiovascular mortality [6-8]. 
In our study, we investigated the association between diabetic 
polyneuropathy assessed by electrophysiological testing and 
chronic complications in type 2 diabetic patients. In our study, 
the prevalence of diabetic retinopathy, nephropathy or auto-
nomic neuropathy was higher in patients with diabetic poly-
neuropathy. Diabetic polyneuropathy was associated with a 
high prevalence of risk factors for macrovascular complica-
tions, such as poor metabolic control, dyslipidemia, and hy-
pertension. In multivariate analysis, diabetic polyneuropathy 
was independently associated with cardiovascular disease (odds 
ratio, 1.801; 95% confidence interval [CI], 1.009 to 3.214). 
  Diabetic sensorimotor polyneuropathy is a form of axonal 
neuropathy associated with diabetes. Among several methods 
for evaluating peripheral neuropathy, nerve electrophysiologi-
cal tests have emerged as important tools for tracing the onset 
and progression of peripheral neuropathy. Recently, the To-
ronto Diabetic Neuropathy Expert Group proposed the use of 
nerve conduction testing as an early and reliable indicator of 
the development of polyneuropathy for epidemiologic surveys 
or controlled clinical trials [9]. The diagnostic sensitivity of 
nerve conduction studies can be improved by additional pa-
rameters such as F-wave. However, as noted by Dr. Ko et al., 
our study has some limitations. Although nerve electrophysi-
ological studies are highly reproducible, sensitive and objec-
tive methods of investigating diabetic polyneuropathy and 
have a key role in excluding the other causes of neuropathy, 
they have limitations in the assessment of small-fiber dysfunc-
tion [10]. Also, there are the discomforts of the procedures and 
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limits on the availability for routine diagnostic evaluation in 
clinical practice [11]. Despite these limitations, the results of 
our study indicate the close relationship between electrophysi-
ologically diagnosed polyneuropathy and cardiovascular dis-
ease in type 2 diabetic patients. Further studies are necessary 
to determine a causal relationship or possible mechanisms be-
tween diabetic polyneuropathy and cardiovascular adverse 
events.
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